Shares of Abiomed (ABMD) are higher after an update on Clinicaltrial.gov showed Abbott Laboratories (ABT) has suspended enrollment of its SHIELD II IDE study after a report of decreased impeller speed at the end of a procedure. The study on a left ventricular support product is aimed at challenging Abiomed’s (ABMD) Impella product in percutaneous coronary intervention patients, Piper Sandler analyst Matt O’Brien told investors in a research note. Shares of Abiomed are up 1% to $310.84 following the news.
previous post
next post